Table 3 Univariate and multivariate analyses of the overall survival in the subgroup of patients who had received perioperative therapy with prior (neo) adjuvant anthracycline- and/or taxane-based regimens (Cox hazard model)

Age ≥ 60 years

1.22

0.83–1.78

0.31

Estrogen receptor negative

1.20

0.81–1.77

0.37

1.99

1.14–3.46

0.015

Central nervous system metastasis

1.20

0.53–2.74

0.66

Bone metastasis

1.63

1.11–2.37

0.012

3.28

1.84–5.82

<0.001

Lung metastasis

1.11

0.76–1.63

0.59

Pleura/lymphangiopathy metastasis

1.21

0.76–1.94

0.42

Lymph node metastasis

1.10

0.75–1.62

0.63

Liver metastasis

1.83

1.24-2.70

0.002

0.72

0.36-1.41

0.34

Visceral metastasis

1.74

1.14-2.63

0.009

3.96

1.94-8.08

<0.001

≥ 3 metastatic sites

1.39

0.95–2.01

0.087

0.55

0.30–1.00

0.050

Disease-free interval (< 24 months)

1.54

1.06–2.24

0.025

1.80

1.04-3.10

0.035

Therapy

Eribulin vs. non-Eribulin

0.86

0.58-1.30

0.48

Early line Eribulin ^a vs. non-Eribulin

1.01

0.65-1.57

0.96

Late line Eribulin ^b vs. non-Eribulin

0.70

0.42-1.15

0.16

0.39

0.21-0.70

0.002